Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is an exploratory clinical study to presume the optimum usage and dosage for a
therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg,
20mg or placebo administered orally in patients with erectile dysfunction. In conclusions,
Patients with erectile dysfunction (ED) were administered placebo, TPN171H 5mg, 10mg or 20mg
30 minutes to 4 hours before sexual intercourse for 8 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Vigonvita Life Sciences
Collaborator:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences